Last reviewed · How we verify
Multicenter,Open,Uncontrolled,Clinical Extension Trial in Subjects With Type I Diabetes Previously Participating in Study HMR1964A/3011 in Belgium
The purpose of this trial is to allow patients to continue on HOE 901 until launch and to gather additional long-term safety data.
Details
| Lead sponsor | Sanofi |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 32 |
| Start date | 2002-11 |
| Completion | 2004-04 |
Conditions
- Diabetes Mellitus
Interventions
- INSULIN GLARGINE
Primary outcomes
- Evolution of efficacy parameters between first study visit (V1) and last study visit (V5) — Mean time interval: 10 months
Countries
Belgium